Alzheimer's Vaccine: AFFiRiS AG Announces Data on Lead Product AD02: Information on Efficacy

VIENNA, Austria, March 11, 2011 - Today, AFFiRiS AG presented the evaluation of secondary
endpoints of a clinical phase I study of their Alzheimer's vaccine AD02. The
programme has been successful in respect of stabilising the cognitive
performance and body weight of subjects during the 18-month study period. In
nine out of twelve subjects who had received the vaccine with adjuvants the
cognitive capabilities were clearly better than would have been expected due
to the disease's progress. In addition, Alzheimer's patients usually lose
weight, since their sense of taste can be impaired or they forget to take in
food. By contrast, a preservation of body weight was recorded in the
vaccinated subjects.

In October 2008, AFFiRiS AG entered into a licensing and
option agreement with GlaxoSmithKline Biologicals. The agreement has a
potential total value of 430 million Euro of which 36 million has already
been paid. "International corporations such as GlaxoSmithKline, Siemens,
Boehringer Ingelheim or Merck have recognized Austria as a business location
and are expanding their research capacities. Policy has created a suitable
framework: a R&D quota of 2.76 percent of GDP in 2010 that should increase to
4 percent by 2020. This will also benefit the dynamic Austrian life sciences,
which is currently making some of the most important deals of the European
biotechnology industry with international institutional investors" comments
Dr. René Siegl, Managing Director of the Austrian Business Location Agency
ABA-Invest in Austria.

Information for editorial staff

ABA - Invest in Austria is a business location agency owned by
the Austrian Ministry of Economic Affairs. It advises interested companies
free of charge on the choice of location, on work and tax law issues, helps
in the search for cooperation partners and assists in contacts with
authorities. Interested companies are looked after by colleagues in the
Vienna headquarters and offices in New York and Tokyo.

    Hanni Grassauer

    ABA - Invest in Austria
    Vienna, Austria
    Tel. +43-1-588-58-57
    E-mail: h.grassauer@aba.gv.at

Internet: www.investinaustria.at

Hanni Grassauer, ABA - Invest in Austria, Vienna, Austria, Tel. +43-1-588-58-57, E-mail: h.grassauer at aba.gv.at